½ÃÀ庸°í¼­
»óǰÄÚµå
1667193

ÇコÄÉ¾î ºÐ¾ß »ý¼ºÇü AI ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

Generative AI in Healthcare Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ß »ý¼ºÇü AI ¼¼°è ½ÃÀåÀº 2023³â 18¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 33.2%ÀÇ °ß°íÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ±Þ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº µö·¯´×°ú ÀÚ¿¬¾î ó¸®(NLP)ÀÇ ¹ßÀü, ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, AI ±â¹Ý ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Àü ¼¼°è ÇコÄÉ¾î µ¥ÀÌÅÍÀÇ ±ÞÁõ µîÀÌ ÀÖ½À´Ï´Ù.

Generative AI in Healthcare Market-IMG1

»ý¼ºÇü AI´Â ÀÇ·á ¿µ»ó ºÐ¼®, ÀÚµ¿ º¸°í, ȯÀÚ Âü¿©¸¦ À§ÇÑ ´ëÈ­Çü µµ±¸ µî Çõ½ÅÀûÀÎ ¾ÖÇø®ÄÉÀ̼ÇÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á ÇコÄÉ¾î »ê¾÷À» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í Á¶Á÷ÀÌ AI ¼Ö·ç¼ÇÀ» ¾÷¹«¿¡ ÅëÇÕÇϵµ·Ï Àå·ÁÇÏ°í ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 18¾ï ´Þ·¯
¿¹»ó ±Ý¾× 202¾ï ´Þ·¯
CAGR 33.2%

¿ëµµº°·Î´Â ÀÇ·á ¿µ»ó ºÐ¼® ¹× Áø´Ü, ½Å¾à °³¹ß, ȯÀÚ Áö¿ø, ¸ÂÃãÇü Ä¡·á µîÀÇ ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. ÀÇ·á ¿µ»ó ºÐ¼® ¹× Áø´Ü ºÐ¾ß´Â Áúº´À» Á¶±â¿¡ Á¤È®ÇÏ°Ô °¨ÁöÇÒ ¼ö Àִ ÷´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2023³â °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.

»ý¼ºÇü AI´Â ÀáÀçÀûÀÎ °Ç°­ À§ÇèÀ» Á¶±â¿¡ ÆÄ¾ÇÇÏ¿© Áø´Ü ´É·ÂÀ» Çâ»ó½Ã۰í, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ °á°ú¸¦ °³¼±ÇÏ°í ¿¹¹æ ÀÇ·á¿¡ ÁýÁßÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϸç, AI ±â¹Ý µµ±¸´Â Á¤È®ÇÏ°í ºü¸¥ ºÐ¼®À» Á¦°øÇÏ¿© ÀÇ·á ¿µ»ó ¹× Áø´Ü¿¡ ´ëÇÑ Ã¤ÅÃÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ, ÇコÄɾî Á¦°øÀÚ, Á¦¾àȸ»ç, ÀÇ·á ÁöºÒÀÚ µîÀ¸·Î ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áß ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â 2023³â¿¡ Áö¹èÀûÀÎ ºÎ¹®À¸·Î ºÎ»óÇÏ¿© ¿¹Ãø ±â°£ÀÌ ³¡³¯ ¶§±îÁö 97¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®¿¡¼­ º´¿ø, Áø·á¼Ò, Áø´Ü ¼¾ÅÍ´Â ¿öÅ©ÇÃ·Î¿ì °£¼ÒÈ­, ȯÀÚ Ä¡·á ÃÖÀûÈ­, ½ºÄÉÁÙ¸µ ¹× ±â·Ï °ü¸®¿Í °°Àº °ü¸® ¾÷¹«¿¡ AI¸¦ Ȱ¿ëÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

»ý¼ºÇü AI´Â ¹Ýº¹ÀûÀÎ ÀÛ¾÷À» ÀÚµ¿È­Çϰí, ¿öÅ©Ç÷οì È¿À²¼ºÀ» ³ôÀ̰í, ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­ÇÔÀ¸·Î½á ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ¿î¿µ ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ÀÚ¿ø ¹èºÐÀ» °³¼±Çϰí ÀçÀÔ¿øÀ²À» ³·Ãç ±Ã±ØÀûÀ¸·Î ºñ¿ë È¿À²ÀûÀÎ ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ±â¿©ÇÕ´Ï´Ù.

ºÏ¹Ì´Â 2023³â 7¾ï 5,870¸¸ ´Þ·¯·Î °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, 2032³â±îÁö Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ Ã·´Ü ÀÇ·á ÀÎÇÁ¶ó´Â ÀüÀÚ ÀÇ·á ±â·Ï(EHR), ¿ø°ÝÀÇ·á ¹× ±âŸ µðÁöÅÐ µµ±¸ÀÇ ±Þ¼ÓÇÑ µµÀÔ°ú ÇÔ²² »ý¼ºÇü AI µµÀÔÀ» À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

  • ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
  • Á¶»ç ¼³°è
    • Á¶»ç Á¢±Ù¹ý
    • µ¥ÀÌÅÍ ¼öÁý ¹æ¹ý
  • ±âº» ÃßÁ¤°ú °è»ê
    • ±âÁØ ¿¬µµ »êÃâ
    • ½ÃÀå ÃßÁ¤ÀÇ ÁÖ¿ä µ¿Çâ
  • ¿¹Ãø ¸ðµ¨
  • 1Â÷ Á¶»ç¿Í °ËÁõ
    • 1Â÷ Á¤º¸
    • µ¥ÀÌÅÍ ¸¶ÀÌ´× ¼Ò½º

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Á¤¹ÐÀÇ·á¿Í Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • ÀÇ·á¿ë ¿µ»ó ó¸® °­È­¿¡ ´ëÇÑ ÁÖ¸ñ »ó½Â
      • AIÀÇ Áøº¸ È®´ë
      • º¥Ã³±â¾÷ÀÇ ÀÚ±Ý Á¶´Þ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ °üÇÑ ¿ì·Á
      • ±ÔÁ¦ Áؼö
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿ëµµº°, 2023-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀÇ·á À̹ÌÁö ºÐ¼®°ú Áø´Ü
  • Drug Discovery & Development
  • ȯÀÚ Áö¿ø°ú ¸ð´ÏÅ͸µ
  • ¸ÂÃãÇü Ä¡·á
  • ±âŸ ¿ëµµ

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2023-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀÇ·á Á¦°øÀÚ
    • ÀÇ·á Á¦°øÀÚ
    • Á¦¾à¡¤»ý¸í°úÇÐ ±â¾÷
    • ÀÇ·á ÁöºÒÀÚ
  • Á¦¾à¡¤»ý¸í°úÇÐ ±â¾÷
  • ÀÇ·á ÁöºÒÀÚ

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2023-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ

Á¦8Àå ±â¾÷ °³¿ä

  • Abridge Al
  • DiagnaMed Holdings
  • ELEKS
  • Google LLC(Alphabet)
  • Insilico Medicine
  • International Business Machines
  • Microsoft
  • NVIDIA
  • Oracle
  • Persistent Systems
  • Syntegra
ksm 25.04.08

The Global Generative AI In Healthcare Market, valued at USD 1.8 billion in 2023, is projected to grow at a robust CAGR of 33.2% from 2024 to 2032. This rapid growth is primarily fueled by advancements in deep learning and natural language processing (NLP), the increasing need for personalized treatments, rising investments in AI-driven healthcare solutions, and the surging volume of healthcare data worldwide.

Generative AI in Healthcare Market - IMG1

Generative AI is transforming the healthcare industry by enabling innovative applications such as medical imaging analysis, automated reporting, and conversational tools for patient engagement. These technological advancements are encouraging healthcare providers and organizations to integrate AI solutions into their operations, driving market expansion.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.8 Billion
Forecast Value$20.2 Billion
CAGR33.2%

In terms of application, the market is divided into segments such as medical image analysis and diagnostics, drug discovery, patient assistance, personalized treatment, and more. The medical image analysis and diagnostics segment led the market in 2023, generating the highest revenue, owing to the increasing demand for advanced tools that enable early and accurate disease detection.

Generative AI enhances diagnostic capabilities by identifying potential health risks at an earlier stage, helping healthcare providers improve outcomes and focus on preventive care. AI-powered tools offer precise and rapid analysis, significantly boosting their adoption in medical imaging and diagnostics.

The market is further segmented by end use, encompassing healthcare providers, pharmaceutical companies, and healthcare payors. Among these, healthcare providers emerged as the dominant segment in 2023 and are expected to reach USD 9.7 billion by the end of the forecast period. Within this segment, hospitals, clinics, and diagnostic centers are increasingly leveraging AI to streamline workflows, optimize patient care, and manage administrative tasks like scheduling and record keeping.

Generative AI plays a crucial role in reducing operational costs for healthcare providers by automating repetitive tasks, enhancing workflow efficiency, and minimizing human errors. These solutions also contribute to better resource allocation and lower hospital readmission rates, ultimately supporting cost-effective healthcare delivery.

North America accounted for the largest revenue share of USD 758.7 million in 2023 and is anticipated to grow significantly through 2032. The region's advanced healthcare infrastructure, coupled with its rapid adoption of electronic health records (EHR), telemedicine, and other digital tools, creates a fertile ground for generative AI adoption. These factors are expected to drive market growth in the coming years.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for precision medicine and treatment
      • 3.2.1.2 Increasing focus on enhancing medical imaging
      • 3.2.1.3 Expanding advancement in AI
      • 3.2.1.4 Increasing venture funding
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Data privacy and security concerns
      • 3.2.2.2 Regulatory compliance
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2023 – 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Medical image analysis and diagnostics
  • 5.3 Drug discovery and development
  • 5.4 Patient assistance and monitoring
  • 5.5 Personalized treatment
  • 5.6 Other applications

Chapter 6 Market Estimates and Forecast, By End Use, 2023 – 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Healthcare providers
    • 6.2.1 Healthcare providers
    • 6.2.2 Pharmaceutical and life sciences companies
    • 6.2.3 Healthcare payors
  • 6.3 Pharmaceutical and life sciences companies
  • 6.4 Healthcare payors

Chapter 7 Market Estimates and Forecast, By Region, 2023 – 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia

Chapter 8 Company Profiles

  • 8.1 Abridge Al
  • 8.2 DiagnaMed Holdings
  • 8.3 ELEKS
  • 8.4 Google LLC (Alphabet)
  • 8.5 Insilico Medicine
  • 8.6 International Business Machines
  • 8.7 Microsoft
  • 8.8 NVIDIA
  • 8.9 Oracle
  • 8.10 Persistent Systems
  • 8.11 Syntegra
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦